Stem definition | Drug id | CAS RN |
---|---|---|
diazepam derivatives | 2336 | 36735-22-5 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.55 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 32 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 27, 1985 | FDA | SCIECURE PHARMA INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Suicide attempt | 68.63 | 35.01 | 26 | 630 | 58142 | 53290268 |
Altered state of consciousness | 47.84 | 35.01 | 16 | 640 | 24820 | 53323590 |
Intentional overdose | 38.51 | 35.01 | 18 | 638 | 67187 | 53281223 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Altered state of consciousness | 49.54 | 35.41 | 20 | 933 | 21977 | 32490596 |
Blood creatine phosphokinase increased | 38.44 | 35.41 | 21 | 932 | 45455 | 32467118 |
Source | Code | Description |
---|---|---|
ATC | N05CD10 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives |
FDA CS | M0002356 | Benzodiazepines |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D006993 | Hypnotics and Sedatives |
FDA EPC | N0000175694 | Benzodiazepine |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Insomnia | indication | 193462001 | |
Suicidal thoughts | contraindication | 6471006 | |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Alcohol intoxication | contraindication | 25702006 | |
Shock | contraindication | 27942005 | |
Depressive disorder | contraindication | 35489007 | |
Substance abuse | contraindication | 66214007 | |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Decreased respiratory function | contraindication | 80954004 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Hypoalbuminemia | contraindication | 119247004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Sleep automatism | contraindication | 247962006 | |
Pregnancy, function | contraindication | 289908002 | |
Severe chronic obstructive pulmonary disease | contraindication | 313299006 | |
Coma | contraindication | 371632003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Porphyria | contraindication | 418470004 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.65 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
15MG | DORAL | GALT PHARMS | N018708 | Dec. 27, 1985 | RX | TABLET | ORAL | 7608616 | June 3, 2028 | METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION |
7.5MG | DORAL | GALT PHARMS | N018708 | Feb. 26, 1987 | DISCN | TABLET | ORAL | 7608616 | June 3, 2028 | METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
GABA A receptor alpha-1/beta-1/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 7.71 | WOMBAT-PK | CHEMBL | |||
GABA A receptor alpha-3/beta-1/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 6.63 | WOMBAT-PK | CHEMBL | |||
GABA A receptor alpha-2/beta-1/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 6.69 | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4019522 | VUID |
N0000147639 | NUI |
D00457 | KEGG_DRUG |
4019522 | VANDF |
C0072828 | UMLSCUI |
CHEBI:8694 | CHEBI |
CHEMBL1200472 | ChEMBL_ID |
DB01589 | DRUGBANK_ID |
C025130 | MESH_SUPPLEMENTAL_RECORD_UI |
4999 | PUBCHEM_CID |
7288 | IUPHAR_LIGAND_ID |
4018 | INN_ID |
JF8V0828ZI | UNII |
35185 | RXNORM |
273189 | MMSL |
5398 | MMSL |
d00917 | MMSL |
001469 | NDDF |
108391004 | SNOMEDCT_US |
371372004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
DORAL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61825-165 | TABLET | 15 mg | ORAL | NDA | 29 sections |
Quazepam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71993-265 | TABLET | 15 mg | ORAL | NDA | 29 sections |